Head-To-Head Review: Cue Biopharma (CUE) versus Its Peers
Cue Biopharma (NASDAQ: CUE) is one of 564 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Cue Biopharma to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
This is a breakdown of recent ratings and recommmendations for Cue Biopharma and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cue Biopharma Competitors||4842||13666||28541||1037||2.54|
Risk and Volatility
Cue Biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Cue Biopharma’s competitors have a beta of 1.31, indicating that their average stock price is 31% more volatile than the S&P 500.
This table compares Cue Biopharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cue Biopharma Competitors||-1,496.37%||-852.97%||-29.81%|
Insider and Institutional Ownership
16.6% of Cue Biopharma shares are owned by institutional investors. Comparatively, 46.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 18.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 15.5% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Cue Biopharma and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cue Biopharma||$1.14 million||-$38.98 million||-4.12|
|Cue Biopharma Competitors||$2.12 billion||$221.77 million||-4.08|
Cue Biopharma’s competitors have higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Cue Biopharma competitors beat Cue Biopharma on 8 of the 13 factors compared.
Cue Biopharma Company Profile
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.